Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora, Inc. (COR) filed an 8‑K announcing its earnings release for the fiscal quarter and year ended September 30, 2025, with the news release furnished as Exhibit 99.1. The company also unveiled a new reporting structure to be used beginning in the first quarter of fiscal 2026: U.S. Healthcare Solutions; International Healthcare Solutions; and Other.
U.S. Healthcare Solutions will include U.S. Human Health (excluding legacy U.S. Consulting Services). International Healthcare Solutions will include Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex. Other will include businesses for which Cencora has begun to explore strategic alternatives, including MWI Animal Health, Profarma, U.S. Consulting Services, and the other components of PharmaLex. Unaudited revised segment information is furnished as Exhibit 99.2. The company scheduled a conference call and webcast at 8:30 a.m. Eastern time.
Cencora (COR) reported insider equity activity. On 10/31/2025, EVP and Chief Data & Info Officer Pawan Verma settled 8,537 restricted stock units into common stock (transaction code M). To satisfy tax withholding, 4,367 shares were disposed (transaction code F), both at a listed price of $337.81 per share. After these transactions, Verma directly owned 4,184.05 shares.
Cencora (COR) reported an insider equity grant. Director Werner Baumann acquired 108 shares of common stock on 11/01/2025, shown at $337.81 per share, bringing his directly held balance to 3,130 shares.
The filing notes this was a grant of restricted stock units in lieu of a $36,250 quarterly cash retainer under the company’s Non‑Employee Director Compensation Program, with delivery of shares deferred until 02/15/2028.
Cencora (COR) reported an insider transaction by a director. On 11/01/2025, the director acquired 89 shares of common stock at $337.81 per share. Following this transaction, beneficial ownership stands at 3,069 shares, held directly.
The filing notes the shares reflect a grant of restricted stock units received in lieu of a $30,000 quarterly cash retainer under the company’s Non-Employee Director Compensation Program.
Cencora (COR) director Dennis M. Nally reported acquiring 104 shares of common stock on 11/01/2025. The shares were issued in lieu of a $35,000 quarterly cash retainer under the company’s Non-Employee Director Compensation Program, at a reported price of $337.81. Following this transaction, Nally beneficially owns 13,477 shares held directly.
Cencora (COR) CEO and Director Robert P. Mauch reported insider transactions on 10/20/2025. He exercised 3,763 stock options at $86.09 per share and sold 5,097 common shares at $326.80 per share under a Rule 10b5-1 trading plan adopted on 11/15/2024.
Following these transactions, he directly owned 37,940 common shares. The non-qualified stock option had an exercise price of $86.09 and an expiration date of 11/13/2026, with the grant previously vesting in four equal installments.
Form 144 filing: A COR insider filed notice to sell up to 31,350 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $10,251,105.07, on or about October 21, 2025 on the NYSE.
The shares comprise 2,000 acquired via restricted stock vesting on September 30, 2023 and 29,350 tied to options granted on November 13, 2019 to be exercised for cash. Over the past three months, the filer reported sales of 14,578, 14,579, and 31,350 shares for gross proceeds of $4,266,543.26, $4,227,618.42, and $9,087,157.00.
Elizabeth S. Campbell, Executive Vice President and director of Cencora, Inc. (COR), reported a sale of 1,886 shares of Cencora common stock on 10/01/2025 at a price of $313.28 per share. Following the transaction, the reporting person beneficially owned 12,824.141 shares. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan adopted on 12/20/2024. The form is signed by Ms. Campbell on 10/03/2025.
Pawan Verma, listed as EVP, Chief Data & Info Officer of Cencora, Inc. (COR), filed an initial Form 3 reporting direct beneficial ownership of 14.05 shares of the issuer's common stock. The event date listed is 10/01/2025. The filing was signed by an attorney-in-fact on 10/03/2025 and includes Exhibit 24 (Power of Attorney).
Cencora, Inc. (COR) filed a Form 144 reporting a proposed sale of 1,886 shares of common stock through Fidelity Brokerage Services LLC on or about 10/01/2025 for an aggregate market value of $590,846.08. The filing shows 193,877,881 shares outstanding, so the shares to be sold represent a de minimis portion of the company.
The securities were acquired on 09/30/2024 through restricted stock vesting from the issuer and the payment is recorded as compensation. The filer certifies they do not possess undisclosed material adverse information. No securities were reported sold by the filer in the prior three months.